Introduction
Klebsiella pneumoniae carbapenemase (KPC) is a serine protease of the molecular class A and was first described in North Carolina in 1996. 1 It is encoded by the bla KPC gene and almost always located within the Tn3-type transposon Tn4401, which is able to insert into plasmids of a huge variety of Gram-negative bacteria. Even though it is still most prevalent in K. pneumoniae, 2 KPC has also been described in other Enterobacteriaceae like Escherichia coli and in non-fermenters like Pseudomonas or Acinetobacter species. 3 This is remarkable, as the latter ones more frequently harbour class B metallo-b-lactamases (e.g. VIM, NDM) and class D b-lactamases, also referred to as oxacillinases (OXAs). In 2007, the first clinical isolate of KPC-producing Pseudomonas aeruginosa was identified in a Colombian hospital 4 and has continuously spread throughout other countries, including the USA, 5 China 6 and Brazil. 7 Interestingly, there has been no report of KPC-producing P. aeruginosa in Europe, yet. As of now we report its arrival in the European Union.
Patient and methods
The clinical isolate was detected in a mid-void urine sample of a patient with chronic myeloid leukaemia on continuous ibrutinib therapy. Comorbidities of the elderly patient included obesity, hyperlipidaemia, hypertension, diabetes mellitus II and consequently chronic kidney disease with impaired renal function. She had received several regimens of antibiotic therapy including quinolones, cephalosporins and piperacillin/tazobactam for suspected pneumonia and urosepsis prior to transfer to our hospital. On admission, at the time of sampling, the patient received meropenem intravenously for externally diagnosed ESBL E. coli bacteraemia. Nasal, pharyngeal and rectal swabs on admission did not yield multiresistant Gram-negative bacilli. Identification of the P. aeruginosa urine isolate and antimicrobial susceptibility testing based on EUCAST criteria were performed using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) and automated microdilution (VITEK2, bioMérieux, Marcy-l'Étoile, France), respectively. MLST was performed as previously described. 8 Briefly, DNA was extracted using the NucleoSpin Tissue Kit (Macherey-Nagel, Düren, Germany) and fragments of seven housekeeping genes (acsA, aroE, guaA, mutL, nuoD, ppsA and trpE) were amplified and sequenced. The ST of the isolate was identified using the sequence definition tool of the P. aeruginosa MLST website (http://pubmlst.org/paeruginosa/). Disc diffusion tests as well as gradient strips (Etest) served as confirmation of the VITEK2 results and additional MIC determination of ceftazidime/avibactam, ceftolozane/tazobactam and colistin (all from Liofilchem srl, Terremoto, Italy). Colistin MIC was confirmed by microdilution. Initial carbapenemase screening of the isolate was performed on the fully automated BD MAX TM PCR platform (Becton Dickinson, Québec, Canada), which amplifies four targets (bla KPC , bla VIM , bla OXA and bla NDM genes encoding KPC 1-17, VIM 1-6 and 8-38, OXA-48-like and NDM, respectively) and detects amplicons via hydrolysis probes (Check-Points Health BV, Wageningen, The Netherlands). 9 Hereupon, the presence of a carbapenemase was further phenotypically analysed with a cloxacillin combined disc test to exclude an intrinsic AmpC cephalosporinase. The modified Hodge test using K. pneumoniae ATCC 700603 as the indicator strain served to confirm carbapenemase expression. Genotypic confirmation was carried out using PCRs for VIM-, IMP-, NDM-, GES-and KPC-encoding genes and Sanger sequencing of amplificates. 10 The bla KPC-2 -carrying plasmid was purified and electroporated into E. coli NEB V R 10-beta (New England Biolabs, Frankfurt am Main, Germany). The presence of bla KPC-2 in transformants was confirmed by PCR; replicon typing was performed as previously described. 11 Plasmid DNA from a bla KPC-2 -positive transformant was sequenced using the Illumina technique.
Results and discussion
The clinical isolate expressed ST235, which has been frequently described in the context of MDR within P. aeruginosa. It has also been frequently reported as a carrier of acquired carbapenemases. KPC-2-producing P. aeruginosa isolates from China expressed ST463, and information on STs is missing in other reports of KPC-2 in this species. Susceptibility testing of the isolate revealed MDR, including resistance to the novel antipseudomonal b-lactam/blactamase inhibitor combinations ceftolozane/tazobactam and ceftazidime/avibactam (Table 1) . Multiplex real-time PCR on BD MAX TM repeatedly detected a bla KPC gene. KPC-2-type carbapenemase production was confirmed using single-locus PCRs as described above. PCR-based replicon typing showed that the bla KPC-2 -carrying plasmid belonged to the Inc type HI1. Plasmid sequence analysis showed the bla KPC-2 gene to be located on a 10 kb contig as part of Tn4401. To the best of our knowledge, this is the first report of bla KPC-2 associated with an IncHI1 plasmid, indicating a continuous spread of KPC-encoding genes into a large variety of transferable plasmids. As no information on the Inc type of other bla KPC-2 -carrying plasmids can be found in the literature, it remains unknown whether the finding of such a strain in Germany is based upon clonal dissemination or international spread of a single plasmid.
The clinical and therapeutic significance of KPC-2-producing P. aeruginosa during the current hospitalization of the patient remains unclear, since the patient showed no clinical signs and symptoms of urogenital tract infection. Furthermore, clinical improvement was achieved with a dose-adjusted intravenous meropenem treatment (2%1 g owing to impaired renal function with a creatinine clearance of 45.8 mL/min/1.73 m 2 according to BIS1) despite a meropenem MIC 32.0 mg/L. Clinical improvement therefore likely resulted from adequate therapy for an E. coli bacteraemia rather than from treatment of a P. aeruginosa isolate considered a mere colonizer. Consistently, we were able to cultivate the same isolate in a rectal swab 8 months after its first detection, indicating long-term colonization. P. aeruginosa colonization remains a major risk factor for consequent invasive disease in critically ill patients with increased morbidity and mortality. 12 Although only a minority of colonized patients will suffer invasive infection, they may still serve as sources of nosocomial transmission. Huge clonal outbreaks with carbapenem-resistant, particularly KPC-2-producing, P. aeruginosa in hospitalized patients have been repeatedly reported. 13 Since similar outbreaks with increased patient morbidity and mortality caused by carbapenemresistant Enterobacteriaceae (CRE) have been recognized for some time, 14 the CDC regularly provides up-to-date infection control recommendations for CRE involving close cooperation between clinical microbiologists, hospital hygienists and clinical practitioners. 15 As with CRE-colonized patients, intensified infection control measures are mandatory for hospitalized patients colonized with MDR Gram-negative non-fermenters since MDR accounts for increased morbidity and mortality. 16 Proof of KPC-2-producing P. aeruginosa will thus result in consequences for patients' further healthcare.
To date, roughly 25% of carbapenem-resistant P. aeruginosa isolates in Germany express carbapenemases. 17 Systematic screening for carbapenemases in P. aeruginosa may therefore not seem worthwhile at first glance. Yet many of the currently recognized carbapenemases rapidly spread even across genus borders, as is the case for KPC-2 located on Tn4401. Colonized patients may serve as a neglected source for the extensive transmission of antimicrobial resistance between a multitude of Gram-negative bacteria. The impressive travel route around the world of KPC-2- Since risk factors for MDR bacteria, such as malignancy 19 or treatment with multiple antimicrobial substances, 20 are regularly present in high-risk populations, we suggest coordinated screening procedures in these patients, as has been recommended for CRE.
Conclusions
Here, to the best of our knowledge, we report the first case of KPC-2-producing ST235 P. aeruginosa in Europe and also for the first time, to the best of our knowledge, the association of bla KPC-2 with the IncHI1 plasmid. These findings underline the importance of molecular methods for carbapenemase identification, plasmid sequencing and MLST for our epidemiological understanding. Since colonization of the gastrointestinal tract along with Enterobacteriaceae may allow horizontal gene transfer and thus inter-genus spread of MDR, it seems justified to screen Gramnegative non-fermenting bacilli for carbapenemases in high-risk patients based on specific phenotypic data obtained with routine antimicrobial susceptibility testing. To date, P. aeruginosa and possibly other non-fermenters might still be a neglected source of unperceived carbapenemase allocation.
